Polish Stem Cell Bank at the 4th Annual International Umbilical Cord Blood Transplantation Symposium.

Between 18th and 21st May the 4th International Symposium on collection, storage and transplantation of umbilical cord blood took place in Los Angeles. A PSCB representative attended this meeting.

Cord blood is a renowned source of haematopoietic stem cells, used in the treatment of many diseases and will probably soon be the source of other stem cells for regeneration medicine. Because of the number of cord blood transplantations carried out worldwide, it is difficult for experts to simultaneously unite to discuss this method within programmes of science conferences. Due to this, the 4th Annual International Umbilical Cord Blood Transplantation Symposium was held in Los Angeles.

This year 400 physicians and cord blood bank representatives from Saudi Arabia, Australia, Brazil, Chile, China, Ecuador, France, Greece, Spain, Netherlands, Hong Kong, India, Israel, Japan, Canada, Colombia, Korea, Kuwait, Malaysia, Mexico, New Zealand, Poland, Singapore, Slovak Republic, Taiwan, Thailand, Venezuela, United Kingdom, Italy and USA took part in the Symposium. Also present was one of PSCB employees – Dariusz Boruczkowski, MD, a children health and transplantology specialist, with 20 years’ experience in haematopoietic cell transplantation for children, including cord blood.

The symposium programme has been divided between two days of theme sessions (consisting of multimedia presentations and panel discussions) involving the most important issues concerning umbilical cord blood:
Session No 1 “Current knowledge on cord blood transplant”
Session No 2 “The choice of the optimal source of stem cells for transplantation”
Session No 3 “Umbilical cord blood transplantation in case of Thalassemia and Sickle-cell Anaemia”
On the first day, during the above sessions, the authors of presentations talked about cord blood transplants preceded by a low-toxicity patient preparation, using double the quantity of cord blood for adult patients (session No 1), results of using cord blood from different sources and of different compatibility (session No 2) and results of cord blood transplants  in given diseases (session No 3).

On the second day of the symposium, the subjects of sessions were as follows:
Session No 4 “Quality in cord blood banking”
Session No 5 “Immune reconstruction after cord blood transplantation (Graft versus Leukaemia Reaction, infection complications and adoptive immunotherapy)”
Session No 6 “Transplantation in children”
Session No 7 “The development of the National Cord Blood Center (US)”
Session No 8 “Cell biology of cord blood cells, ex-vivo expansion, regeneration medicine”
The topics discussed on the second day concerned inter alia possibilities of improving the quality of cord blood choice and preparation (session No 4), results connected with the restoration of the hematopoietic system functions and treatment of eventual disease recurrence (session No 5), results of cord blood transplantation compared to transplantations of hematopoietic stem cells from other sources (session No 6).

A separate session, consisting of presentations (shown by a government representative) and a panel discussion, concerned the plans of development of an American system facilitating access to hematopoietic stem cell transplantations including those from cord blood (session No 7).
The last session of day and the whole Symposium mostly concerned matters of ex-vivo stem cell expansion and possibilities of cell differentiation into various human tissues.

A large number of issues and problems were brought up systematically during a separate yearly international symposium devoted only to cord blood transplantation. It testifies the total acceptance of this treatment method of many cancerous and non-cancerous diseases and the possibilities of using cord blood transplantation in the future for other diseases, once approved safe and successful.

Polish Stem Cell Bank S. A